Annals of Oncology Advance Access originally published online on June 1, 2006
Annals of Oncology 2006 17(8):1263-1268; doi:10.1093/annonc/mdl104
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
1 Medical University of South Carolina, Charleston, South Carolina, USA; 2 St. Petersburg City Clinical Oncology Center; 3 St. Petersburg Pavlov State Medical University, St. Petersburg; 4 City Oncology Hospital #62, Moscow, Russia; 5 American BioScience, Inc., Santa Monica, California, USA
* Correspondence to: Dr M. R. Green, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA. Tel: +1 (843) 762–7325; Fax: +1 (843) 762–5623; E-mail: mgreen{at}nmcr.com
Background: Abraxane® (ABI-007) is a novel 130-nm, albumin-bound (nabTM) particle form of paclitaxel designed to utilize endogenous albumin pathways to increase intratumor concentrations of the active drug. This multicenter phase II study was designed to evaluate the efficacy and safety of Abraxane 260 mg/m2 every 3 weeks in patients with non-small-cell lung cancer (NSCLC).
Patients and Methods: Patients with histologically confirmed, measurable NSCLC received Abraxane as first-line therapy.
Results: Forty-three patients were enrolled. The overall response rate was 16%; the disease control rate was 49%. Median time to progression was 6 months, and median survival was 11 months. The probability of not having progressed by 1 year was 13%; the probability of surviving 1 year was 45%. No severe hypersensitivity reactions were reported despite the lack of premedication; 95% of patients were treated without dose reduction. Two patients (5%) discontinued therapy because of treatment-related toxicities (neuropathy, fatigue [1 each]). No grade 4 treatment-related toxicity occurred.
Conclusions: Abraxane 260 mg/m2 administered IV over 30 min without premedication was well tolerated. Significant tumor responses and prolonged disease control were documented in this group of patients with NSCLC. Exploration of higher doses of ABI-007 alone and in combination with other drugs active in NSCLC is warranted.
Key words: ABI-007, nabTM, nanoparticle, nab-paclitaxel
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin Therapeutic Nanoparticles for Drug Delivery in Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1310 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Rizvi, G. J. Riely, C. G. Azzoli, V. A. Miller, K. K. Ng, J. Fiore, G. Chia, M. Brower, R. Heelan, M. J. Hawkins, et al. Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2008; 26(4): 639 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Onc., December 1, 2007; 18(12): 2009 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason 130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874. [Abstract] [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Multicentre clinical trials: Is practice of authorship in place fair?
- Sergei Tjulandin, et al.
- Annals of Oncology, 21 Sep 2006 [Full text]